SQI Diagnostics Inc SQIDF

TORdx is key to hundreds of millions of dollars+ for others

[FactFinder1994]

SQI is pioneering an advanced diagnostic test that increases the chance of successful lung transplant by assessing the health of the donor organ before transplant surgery. The Company’s TORdxTM LUNG Test measures inflammation at the molecular level to assess the health of the donor lung, enabling surgeons to transplant healthy lungs that otherwise would have been rejected; there is currently no other such test. Upon receipt of regulatory approval of the TORdxTM LUNG Test we will scale up our development for other significant transplant market opportunities in the kidney and liver transplant sectors.

SQI’s clinical research partner at University Health Network (UHN), is leading force in the transportation of healthy donor lungs available for transplant by supporting perfusion centers across North America. Implementation of Ex-Vivo Lung Perfusion (EVLP) procedures (FDA approved in 2019) has enabled lung transplant centers to increase the availability of donor lungs for transplant by nearly two-fold. Upon receipt of FDA market approval for the TORdxTM LUNG Test, SQI intends to leverage its product offering within the EVLP market and direct to transplant hospitals. UHN is considered a world leader in the lung transplant business and our TORdxTM LUNG Test a key piece of this new solution.